The FDA's "radical transparency", up to a point
A newly published cache of CRLs includes six novel oncology drugs.
More problems for BioNTech & Roche’s neoantigen shot
Autogene cevumeran goes on hold in adjuvant bladder cancer.
Regeneron enters the T-cell engager arena
Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
Dizal's US first; now what?
Zegfrovy is approved in a best-case setting, but Dizal has no US presence.
A solid tumour Car-T first?
Satri-cel is filed for gastric cancer approval in China.
Better late than never for Datroway in lung cancer
Astra/Daiichi have trumped Gilead’s Trodelvy with a lung cancer approval.
Opinion: dealing with failure, iTeos style
When your investment case breaks down, why not just do the decent thing?
